Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17162628 | 0.82 | KMT2A (0.52) | KMT2AMEN1RAB9ACYP1A2CYP2C19 | |
| SCHEMBL24615932 | 0.78 | RAB9A (0.41) | KMT2AMEN1RAB9ANPC1ALDH1A1 | |
| SCHEMBL7145573 | 0.78 | RAB9A (0.41) | KMT2AMEN1RAB9ANPC1ALDH1A1 | |
| SCHEMBL7573899 | 0.77 | KMT2A (0.41) | KMT2AMEN1RAB9ACYP1A2CYP2C19 | |
| SCHEMBL7573905 | 0.77 | MAPT (0.59) | KMT2AMEN1RAB9ACYP1A2CYP2C19 | |
| SCHEMBL14378535 | 0.75 | SLC18A3 (0.42) | KMT2AMEN1RAB9ANPC1ALDH1A1 | |
| SCHEMBL4560035 | 0.75 | KDM4E (0.42) | KMT2AMEN1RAB9ACYP1A2CYP2C19 | |
| SCHEMBL4500454 | 0.75 | KDM4E (0.42) | KMT2AMEN1RAB9ACYP1A2CYP2C19 | |
| SCHEMBL13712017 | 0.75 | KMT2A (0.40) | KMT2AMEN1RAB9ACYP1A2CYP2C19 | |
| SCHEMBL4558887 | 0.75 | KMT2A (0.40) | KMT2AMEN1RAB9ACYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470123-A1 | BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, RELATED COMPOSITIONS AND METHODS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-10-27 | — | — | EP | claimed |
| US-20040067994-A1 | BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS | PAGET STEVEN D (US) | 2004-04-08 | — | — | US | claimed |
| US-6608081-B2 | Treating pneumonia | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-08-19 | — | — | US | claimed |
| WO-2003064415-A1 | BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIAL, RELATED COMPOSITIONS AND METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-08-07 | — | — | WO | claimed |
| US-20020161029-A1 | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-31 | — | — | US | claimed |
| EP-1470123-A1 | BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, RELATED COMPOSITIONS AND METHODS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| US-6770664-B2 | PYRROLO(3,4-C)PYRAZOL-5(4H)-YL)-3-FLUOROPHENYL)-2-OXO-5 -OXAZOLIDINYL)METHYL)ACETAMIDE DERIVATIVES; BACTERICIDES AGAINST DRUG RESISTANT STAPHYLOCOCCUS, STREPTOCOCCUS, AND/OR ENTEROCOCCUS | PAGET STEVEN D (US) | 2004-08-03 | — | — | US | disclosed |
| US-20040067994-A1 | BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS | PAGET STEVEN D (US) | 2004-04-08 | — | — | US | disclosed |
| US-6608081-B2 | Treating pneumonia | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-08-19 | — | — | US | disclosed |
| WO-2003064415-A1 | BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIAL, RELATED COMPOSITIONS AND METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| US-20020161029-A1 | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161029-A1 | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods | OXA1L, NDUFS3, CYCS | KMT2A 3290/4885MEN1 4298/4885RAB9A 3273/4885 |
| US-20040067994-A1 | BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS | OXA1L, NDUFS3, CYCS | KMT2A 3290/4885MEN1 4298/4885RAB9A 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.